We evaluated the effect of individual and collective factors on the outcome of allogeneic haematopoietic stem cell transplantation (HSCT) at 35 French centres. Individual factors included patient and transplantation characteristics. Collective factors were related to the period and centre in which HSCT was performed. Two centre factors were studied: centre experience (ie number of HSCT performed during the study period) and the type of centre (paediatric or adult). All patients receiving a first allogeneic HSCT in France between 1st January 1993 and 31st December 1997 were included in the study. The follow-up period ended on 31st December 1997. The final sample included 2756 subjects. We analysed overall survival (OS) and transplant-related mortality (TRM). Prognostic factors were identified by univariate and multivariate analysis, using Cox models. We found that centre experience had no significant effect on outcome. However, survival rates, whether determined on the basis of OS or TRM, were significantly higher in paediatric centres than in adult centres. Residual heterogeneity was found between adult centres. Survival rates were significantly higher for HSCT performed after 1st January 1996 than for those performed before this date.
evaluation; centre effect; period effect; survival analysis; transplant related mortality The last 20 years have seen an increase in the use of allogeneic haematopoietic stem cell transplantation (HSCT) as an alternative to chemotherapy in patients with haematological malignancies. 1 Many European centres, including 36 in France, currently perform allogeneic HSCT. The widespread nature of this activity makes it necessary to evaluate outcomes. Outcome may depend on factors originating from the patient, the disease or aspects of transplantation. Once these factors have been taken into account, efforts should be made to determine the variability in outcome according to the centre at which transplantation was performed or over time. We describe here a retrospective evaluation of allogeneic HSCT outcomes at French centres that was carried out by the Etablissement Franc¸ais des Greffes (EFG), the French Transplantation Agency. This organisation is responsible for recording and evaluating the outcomes of organ, tissue and cell transplantation in France. The objective of this evaluation was to determine the effects of centre and period in which HSCT was performed after adjusting for patient and transplantation characteristics.
Centre effects have been widely investigated in various medical and surgical fields, [2] [3] [4] [5] [6] [7] [8] [9] [10] including organ transplantation. [11] [12] [13] [14] Several factors may account for such effects, including the facilities available, procedures used, and the skills and experience available at the centre. Most of the surveys published to date only analysed the influence of experience at the centre. In the field of allogeneic HSCT, four studies have been conducted to date, based on data from the European Group for Blood and Marrow Transplantation, 15, 16 the International Bone Marrow Transplantation Registry 17 and the Japan Society for Haematopoietic Cell Transplantation. 18 Three of these studies concerned a specific population of patients with leukaemia receiving grafts from an HLA-identical sibling, [15] [16] [17] whereas the fourth included patients with various diagnoses and HLA disparities between donor and recipient. 18 One of these studies found that the observed centre effect could be accounted for, at least in part, by centre experience. 16 The other studies simply analysed the effect of centre experience on outcome. No overall consensus was obtained, as three of these studies found a correlation whereas the fourth did not. 15 Improvements in survival over time have been clearly demonstrated for organ transplantation. [19] [20] [21] [22] Such improvements have also been shown for allogeneic HSCT, in various diseases: chronic-phase chronic myelogenous leukaemia, 23 acute or chronic myelogenous leukaemia, 24 acute lymphoblastic leukaemia in second complete remission, 25 and primary immunodeficiencies. 26 In all these studies, increases in survival were attributed to improvements in supportive care and graft-versus-host disease (GVHD) prevention.
Contrary to most previous studies, we did not restrict our population to patients with a specific diagnosis or to recipients having a particular relationship or histocompatibility with the donor. Moreover, in this paper, period effect and centre effect were investigated simultaneously. Centre effect was analysed by means of two factors: centre experience and type of centre (paediatric or adult). After taking these factors into account, residual heterogeneity among centres was evaluated.
Patients and methods

Data
The population initially selected consisted of all patients who first underwent allogeneic HSCT between 1st January 1993 and 31st December 1997 in France: 2980 patients, treated at 36 centres. We did not take second or subsequent HSCT into account because we aimed to evaluate the ability of each centre to improve patient survival rather than to compare the success of HSCT at different centres. We excluded patients with the following six diseases, each of which accounted for less than 2.5% of the entire population: chronic lymphocytic leukaemia, Hodgkin's disease, myeloma, haemoglobinopathy, solid tumours, myeloproliferative syndrome (other than CML). We also excluded one centre at which only 10 HSCT were performed during the study period. In total, 2756 patients receiving transplants at 35 centres were considered eligible for inclusion in the analysis.
The data initially retained for analysis were all items recorded in the EFG database concerning patient survival, relapse, and potential prognostic factors. We assessed the quality of these data by means of an external audit of the 36 centres initially retained before the application of the exclusion criteria. At each centre, we selected 20 patients at random (for centres performing less than 20 HSCT, all patients were selected). For each patient, we compared the data in the local medical file with those in the EFG database. For each item, we calculated the percentage discordance globally and separately for each centre. For items involving dates (date of diagnosis, date of birth, date of HSCT, date of relapse, date of death, date of last followup), discordance was defined as a difference of more than 15 days between the value indicated in the medical file and the value recorded in the EFG database.
Overall, we compared 687 medical files with the information recorded in the EFG database. The quality of the database was found to be insufficient for two items: date of diagnosis -used to calculate the time from diagnosis to transplantation -and date of relapse. The percentage discordance for these two items was 34 and 32%, respectively. For all other items, the discordance was less than 4%, which was considered satisfactory.
Two outcomes were analysed: overall survival (OS) and transplant-related mortality (TRM), defined as death from any cause in the absence of relapse. Both outcomes provide a means of assessing patient survival. For OS, we used the date of first HSCT, the date of last follow-up after the last HSCT and survival status at this date (dead or alive) for each patient. For TRM, we also used occurrence of relapse and date of relapse, despite the poor quality of these data. The follow-up end point was 31st December 1997. Eight individual or collective potential prognostic factors for OS and TRM were defined from items recorded in the EFG database (Table 1) . For patients undergoing more than one HSCT, we used only the values of these factors at first HSCT. Age of the patient at transplantation was divided into five classes. The first class included patients under 16 years old, which corresponds to the usual age below which a patient is transplanted in a paediatric centre. The four other classes corresponded to the quartiles of over 16-yearold patients. Given the small number (12) of transplant performed with a mixed source of cells (cells from bone marrow and peripheral blood), this category was grouped with peripheral blood, because in this kind of transplantation, the major part of the graft is usually composed of peripheral blood stem cells. Time from diagnosis to transplantation was not studied, given the poor quality of the data concerning date of diagnosis.
Centre experience was treated as a discrete variable (Table 1) . It was defined from the number of allogeneic [17; 28] ) and the median time for TRM was not reached.
Statistical methods
For each outcome studied (OS or TRM), the same statistical method was used.
Firstly, we carried out univariate analysis to study the relationships between each outcome and each potential prognostic factor listed in Table 1 . We used the univariate Cox model and the Likelihood Ratio Test. [29] [30] [31] If the hazard ratio in several categories of a given factor was not significantly different, these categories were grouped.
Secondly, all individual and collective factors listed in Table 2 were included in a multivariate Cox model. A stepwise multivariate analysis was performed. Factors significantly related to each outcome (Po0.05) were retained.
Thirdly, based on the previous model, three other models were built, in which centre-related factors were replaced by Table 2 Results of the univariate analysis for overall survival (OS) and transplant-related mortality (TRM) one variable for each centre (the baseline being the centre with the highest number of transplants), by one variable for each paediatric centre or by one variable for each adult centre. All these models were compared to the previous one using the Likelihood Ratio Test, 31 to check if there was any residual heterogeneity between centres.
In univariate or multivariate models including period effect, each patient's follow-up was truncated to 1 year after transplantation, for patients who received HSCT before 1st January 1997. As the follow-up end point for the whole sample was 31st December 1997, this meant that all patients had approximately equivalent durations of follow-up (ie 1 year or less).
Results
Results of the univariate analysis are shown in Table 2 . The effects of sex of recipient, sex of donor, source of cells, centre experience and period were not significant. After grouping categories with similar hazard ratios, diagnosis was finally divided into four classes, and age into three classes. They were both found to be significant, as were HLA compatibility and type of centre. A global centre effect was found (P ¼ 0.0002 for OS and P ¼ 0.0001 for TRM). The results of the multivariate analysis are given in Table 3 . Individual factors retained were age, HLA compatibility and diagnosis. Regarding collective factors, the period effect was found to be significant with a cutoff point at 31st December 1995. The estimated hazard ratio was 0.88 for OS (P ¼ 0.0419) and 0.87 for TRM (P ¼ 0.0483). The probability of overall mortality and the probability of TRM were thus lower for HSCT performed after 1st January 1996 than for those performed before that date. Centre experience was not found to be significant. However, survival rates, whether determined on the basis of OS or TRM, were significantly higher for paediatric centres than for adult centres with a hazard ratio of 0.75 for OS (P ¼ 0.0015) and 0.71 for TRM (P ¼ 0.0009). The test of residual heterogeneity between centres was significant only for adult centres (P ¼ 0.0020 for OS and P ¼ 0.0094 for TRM). Paediatric centres were found to be homogeneous. Thus, the best model was that including the factors listed in Table 3 and one variable for each adult centre. The hazard ratios obtained with this model were very similar to those presented in Table 3 .
Discussion
We evaluated the results of allogeneic HSCT at 35 centres in France, based on data recorded from 1993 to 1997 in the EFG database. The aim was to determine the effect of period and centre-related factors on outcome, after adjusting for patient and transplantation characteristics.
This study was undertaken by the EFG at the beginning of 1997. It was decided that HSCT performed during the previous 5 years would be included. Between January and April 1998, centres provided their data for HSCT performed until 31st December 1997. The follow-up end point was fixed at 31st December 1997 so that centres could be homogeneous regarding follow-up. The drawback is that not much information was available for HSCT performed in the months just before 31st December 1997. This is the Table 3 Multivariate analysis; prognostic factors retained for overall survival (OS) and transplant-related mortality (TRM) HSCT: evaluation of centre and period effects F Mesnil et al first time that HSCT outcomes have been evaluated in France. It was thus important to check the quality of the data used. An audit of the database was performed. After the audit, data on HSCT performed after 1997 were collected in the EFG database and the follow-up of HSCT performed before 31st December 1997 was updated. However, we did not take into account this information a posteriori, because the quality of the data recorded was not checked and may depend on the centre. We first identified individual prognostic factors from the variables listed in previous publications for which data were available and satisfactorily recorded in the EFG database. 32 CMV status was not recorded during the period studied. CMV status is usually negative in young patients. Thus, in this analysis, the effect of CMV status may be partially covered by the effect of age and by the effect of type of centre. However, for a given age, and a given type of centre, centres probably had the same policy regarding CMV status, performing HSCT on positive and negative patients. Therefore, the omission of CMV status in the analysis probably did not have major consequences. We do not consider it could explain the residual heterogeneity found between adult centres. Details about the conditioning regimen were not available in the database. However, the population studied was relatively homogeneous regarding this factor, as during this period all patients with haematological malignancies received a myeloablative conditioning regimen. Other factors not explicitly taken into account are redundant with the factors included in the analysis. For example, the geno-or pheno-identical nature of HSCT is correlated with the factor 'HLA compatibility'. The number of treatment courses before HSCT is correlated with disease status at transplantation and is therefore partially covered by the diagnosis classes 'low-risk leukaemia' and 'high-risk leukaemia'. The source of cells was taken into account in the analysis, but was not found to be significant in multivariate analysis.
One objective of the study was to determine whether the centre affected outcome. It was not possible to use the data from one centre because too few HSCT were performed for satisfactory analysis with the standard statistical models used. More complex statistical methods, based on mixedeffect models, which can take into account a small number of observations per centre, 33 could be used to evaluate the results of all centres regardless of the number of HSCT performed.
Centre effect was explored by means of two centrerelated factors: centre experience and type of centre (paediatric or adult). Centre experience was defined as the number of allogeneic HSCT performed at the centre during the study period. It was treated as a discrete variable and was found to have no effect on outcome. Similar results were obtained with the data of the European Bone Marrow Transplantation Registry, 15 but the analysis of three other data sources resulted in a different conclusion. [16] [17] [18] These studies are not easy to compare because they included different kinds of patients and ways of representing centre experience. The data set used by the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation was very different from ours. It was nonexhaustive because only 13 European centres were included. 16 Moreover, only patients with acute myeloblastic leukaemia receiving allogeneic HSCT from an HLAidentical sibling donor were considered (522 patients). The cutoff point used to separate centres according to experience was high (39 HSCT per year). A significant difference in TRM was observed between the two groups. In our data set, only one centre performed more than 39 allogeneic HSCT per year. The other study based on the European Bone Marrow Transplantation Registry included 1957 patients with three kinds of leukaemia, receiving allogeneic HSCT from an HLA-identical sibling donor at 52 centres. 15 Centres were classified into three groups (mean number of allogeneic HSCT per year below 2, between 2 and 9, higher than 9) corresponding to 46, 37, and 17% of centres respectively. No correlation was observed between outcome and experience. The study performed on data from the International Bone Marrow Transplantation Registry included 1313 patients with three kinds of leukaemia, receiving allogeneic HSCT from an HLAidentical sibling donor at 86 centres. 17 The cutoff point used to distinguish centres was five allogeneic HSCT per year. The proportion of centres performing less than five allogeneic HSCT per year was 24%. The authors found a difference in outcomes for these two groups. However, no correlation between volume and outcome was observed in the group performing more than five allogeneic HSCT per year. The data from the Japan Society for Haematopoietic Cell Transplantation are more comparable with ours, as they included 3134 patients undergoing transplantation at 121 centres, with various diagnoses and all kinds of HLA disparities and relationships between donors and recipients. 18 Centres were classified into three groups (mean number of allogeneic HSCT per year less than 4, between 4 and 11, higher than 11) corresponding respectively to 8, 24, and 68% of the centres. The authors found a correlation between volume and outcome only for transplants from a sibling donor. There is therefore no consensus concerning the effect of centre experience on the outcome of allogeneic HSCT because discrepancies are observed if studies performed on similar kinds of patients, or with similar cutoff points to define experience, are compared.
Type of centre, that is paediatric or adult, was found to have a significant effect on outcome, with higher survival rates for paediatric centres. Residual heterogeneity was observed between adult centres, whereas paediatric centres were found to be homogeneous. This raises the following questions: (i) To what extent does the effect of type of centre overlap with the effect of age in the analysis? (ii) How can we explain these results? There was not a perfect overlap between type of centre and age class in our analysis. Paediatric centres theoretically perform HSCT on patients under 16 years of age. However, they also treat some patients of over 16 years who are diagnosed in the centre a few years before their first HSCT. Similarly, adult centres sometimes include a few patients under 16 years. The univariate analysis grouped the three lower age classes because of nonstatistically different hazard ratios. However, even if we introduce the lower age class (under 16 years) together with the two highest age classes and the type of centre in the stepwise multivariate analysis, the retained model includes type of centre and not the lower age class. This means that age may not be the only reason why survival rates were higher in paediatric centres. Other reasons for this may be that paediatric centres perform HSCT using younger donors than adult centres and on patients who are more likely to be CMV-negative. The homogeneity found among paediatric centres may be partially explained by the relative homogeneity of patients, especially regarding diagnosis and age of donor.
Another purpose of our study was to detect a potential period effect on HSCT outcomes. Different cutoff points were used and a significant improvement in outcomes was observed after 1st January 1996. There are two potential reasons for this. Firstly, since 1996, the development of molecular typing and donor lymphocyte infusions, respectively to detect and to treat relapse may have reduced relapse-related mortality rates. Secondly, more effective prevention and treatment of infections and GVHD may have influenced TRM rates. Other studies focusing on the period effect on HSCT outcomes [23] [24] [25] have been performed in different periods and identified different cutoff points for the observed period effects (1988, 1986 , and 1998), illustrating the constant improvement of this procedure.
In conclusion, we found that HSCT outcomes were not influenced by centre experience, but differed according to the type of centre. Residual variation was found for adult centres and a period effect was observed. Factors other than centre experience may contribute to the betweencentre variability of outcomes: material and human facilities, technical aspects of transplantation (eg supportive care, GVHD prophylaxis), patient recruitment and the skills available at the centre. Although a period effect is often observed, it has generally been analysed in retrospective studies, meaning that it is detected after the event. In future studies, it would be interesting to identify and to analyse in detail the components of the centre effect and to develop statistical methods for detecting changes in outcomes in real time, both globally and separately for each centre. Analyses of this type will make it possible to determine more quickly the potential causes of failure and to define criteria for quality control policies.
